CSL hits back at critics with profit growth
Melbourne biotechnology giant CSL has hit back at doubters posting a massive rise in revenues for the year. The company, which has been questioned by analysts about its recent acquisition of the Vifor pharmaceutical business, reported revenues up 31 percent at constant currency value to $13.31 billion for FY23. Sales for CSL Vifor in the…
